Watson, Andrx Extend Merger Deadline

FTC looking for more time to review deal.

Drug makers Watson Pharmaceuticals Inc. and Andrx Corp. said Monday they extended the deadline for their merger agreement to allow more time for the Federal Trade Commission to review the acquisition.

In May, the FTC requested more information on their proposed merger. Watson agreed to acquire Andrx for $25 per share, or about $1.9 billion, in March.

The deadline has been extended to Nov. 13 from Sept. 12.

More in Supply Chain